CFTR modulators approval represents a breakthrough in CF care because a significant improvement in patient’s lung function (evaluated by measurements of FEV1 (forced expiratory volume in 1 s)) has been observed (Table 1). The gene discussed is CFTR; the disease is cystic fibrosis.